Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics, Plc is soliciting shareholder votes at its 2026 Annual General Meeting to be held on June 30, 2026 at 2:30 p.m. London time. The Notice and Proxy Statement ask shareholders to vote on routine corporate matters including adoption of the 2025 statutory accounts, re-election of six Class A directors, ratification of auditors and advisory votes on executive compensation.
The board also seeks authority for equity actions tied to Nasdaq compliance: (i) approval related to an ELOC Purchase Agreement (up to $25,000,000 aggregate purchase right), (ii) shareholder approval to permit issuance of warrants and ADSs to purchase up to 4,411,764 ADSs and 117,647 placement agent ADSs, and (iii) broad allotment and pre-emption disapplication powers through June 30, 2031. The Proxy Statement reports 64,352,739,523 ordinary shares outstanding as of June 1, 2026 and that each ADS represents 80,000 ordinary shares.
Akari Therapeutics entered into a securities purchase agreement for a private placement of 1,470,588 American Depositary Share units. Each unit consists of one ADS or a pre-funded warrant plus Series H, I and J warrants, at an ADS unit purchase price of $3.74 or $3.739 for pre-funded units.
The transaction is expected to generate approximately $5.5 million in gross proceeds before about $125,000 of placement agent fees, with closings anticipated around May 27, 2026, June 15, 2026 and July 15, 2026. Net proceeds are earmarked for working capital and general corporate purposes.
Investors receive warrants exercisable at $3.74 per ADS, and the placement agent receives a 2% cash fee plus 117,647 ADSs, both subject to shareholder approval. Akari plans to file a registration statement to register the resale of the shares and warrant shares purchased in this offering.
Akari Therapeutics reported a sharply higher quarterly loss as it wrote down key intangible assets and flagged serious liquidity pressure. For the three months ended March 31, 2026, the company recorded a net loss of $14.5 million, driven mainly by non-cash impairment charges of $3.7 million on its AKTX‑101 in‑process R&D and $8.4 million on goodwill related to the Peak Bio merger. Operating expenses rose to $15.8 million from $3.5 million a year earlier as ADC preclinical development spending increased and the impairments were recognized.
Cash and restricted cash fell to $2.8 million at March 31, 2026, with operating activities using $2.5 million of cash in the quarter. Management states this balance is insufficient to fund operations for 12 months and concludes there is “substantial doubt” about Akari’s ability to continue as a going concern, estimating existing cash funds operations only into June 2026. The company highlights an equity line with White Lion for up to $25 million, but had not drawn on it by quarter‑end. Akari remains a pre‑revenue oncology company, focused on advancing lead ADC candidate AKTX‑101 toward IND‑enabling work and a planned first‑in‑human study around mid‑2027.
Akari Therapeutics, Plc notified the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because management and counsel devoted substantial time to matters relating to a previously announced upcoming public offering. The company expects to file within the five-day extension provided by Rule 12b-25. The filing states the quarterly results will reflect a material non-cash impairment charge triggered primarily by a sustained decline in market price and market capitalization, and that management evaluated recoverability and fair value under U.S. GAAP.
Akari Therapeutics is registering up to 1,139,818 American Depositary Shares (ADSs) with accompanying Series H and Series I warrants, plus related pre-funded and placement agent warrants, in a best-efforts primary offering. Each ADS represents 80,000 ordinary shares. The assumed combined public offering price is $6.58 per ADS with attached warrants, matching the May 7, 2026 Nasdaq closing price. If all ADSs are sold and no pre-funded warrants are issued or warrants exercised at closing, Akari estimates net proceeds of about $6.7 million, to fund research and development, working capital and general corporate purposes.
The structure allows certain investors to buy pre-funded warrants instead of ADSs to manage ownership caps of 4.99% or 9.99%. Common warrants are immediately exercisable, with Series H expiring in five years and Series I in 12 months. The offering has no minimum, so Akari could raise substantially less than the maximum, which its own risk disclosures say may limit its ability to execute its business plan. As of December 31 2025, the company had 90,536,879,533 ordinary shares outstanding and focuses on preclinical antibody-drug conjugate oncology programs, including lead candidate AKTX-101.
Akari Therapeutics, Plc filed a Post-Effective Amendment to its Form S-1 to register for resale up to 867,023 ADSs, each representing 80,000 ordinary shares, or 69,361,812,000 ordinary shares in the aggregate. The filing updates the prospectus to reflect a March 31, 2026 Ratio Change (one ADS now = 80,000 ordinary shares) and incorporates exchange-act reports by reference. The resale securities are held by selling stockholders; Akari will not receive proceeds from resale transactions but may receive up to $8.9 million if warrants are exercised for cash. The ADSs trade on Nasdaq under the symbol AKTX and the prospectus discloses outstanding shares and various warrant, option and RSU counts as of December 31, 2025.
Deutsche Bank Trust Company Americas filed Post-Effective Amendment No. 4 to Form F-6 for Akari Therapeutics, Plc (f/k/a Celsus Therapeutics) to change the American Depositary Share ratio so that one ADS represents eighty thousand (80,000) ordinary shares. The amendment is dated March 18, 2026 and the filing was signed on March 31, 2026. The amendment revises the form of ADR/Receipt and updates the Deposit Agreement; existing receipts need not be exchanged but will be governed by the amended terms when surrendered or reissued.
Akari Therapeutics, Plc is an oncology company focused on next‑generation antibody‑drug conjugates built around its proprietary PH1 payload, which targets RNA splicing to kill cancer cells and generate immune‑stimulating neoantigens. The lead ADC, AKTX‑101, targets Trop‑2 and has shown stronger preclinical tumor killing and favorable tolerability versus existing Trop‑2 ADCs, including synergy with checkpoint inhibitors.
Akari is preparing AKTX‑101 for IND‑enabling work and aims to start a first‑in‑human Phase 1 trial by late 2026 or early 2027, while advancing CEACAM5‑directed AKTX‑102. The company highlights a history of operating losses, material weaknesses in internal controls, significant capital needs, and extensive regulatory and competitive risks. It relies on WuXi Biologics/XDC for GMP manufacturing and holds a global patent estate around PH1, AKTX‑101 and broader spliceosome‑modulating ADC biology.